• Polyrizon reported successful biocompatibility results for its NASARIX Allergy Blocker nasal spray, supporting progress toward a first-in-human clinical trial.
• Results have been presented, with all required biological safety tests meeting pre-set acceptance criteria.
• The outcome supports the product’s non-clinical safety package, a key step in its clinical and regulatory path for a drug-free nasal barrier for seasonal allergies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-074946), on July 02, 2026, and is solely responsible for the information contained therein.